Co-Authors
This is a "connection" page, showing publications co-authored by GORDON B MILLS and GEORGE R BLUMENSCHEIN.
Connection Strength
0.318
-
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol. 2012 Sep 10; 30(26):3287-96.
Score: 0.107
-
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
Score: 0.106
-
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.
Score: 0.052
-
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
Score: 0.027
-
cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
Score: 0.026